Updated:
Omega Funds
Omega Funds invests in the future of medicine. The firm aims to invest in exceptional founders and entrepreneurs and impactful products and platforms across...
Omega Funds
Omega Funds invests in the future of medicine. The firm aims to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others. It has helped bring 55 products to patients.
General information
Firm type
Private Equity
Year founded
2021
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Principals
Eric Cooper
Deirdre Cunnane
Francesco Draetta
Claudio Nessi
Otello Stampacchia
Bernard Davitian
Michelle Doig
Saoussen Ben Halima
Noelle Hutchins
Kurt Kongtong-Gallagher
Vincent Ossipow
Roshawn Blunt
Maria Koehler
John Maraganore
Menelas Pangalos
Sanjaya Singh
Philipp Bliedung
Gilchrist DiPrete
Jonathan Hempton
Brent Jiang
Mark Russell
Heather Weekley
Susana Carella
Estelle Decosterd
Denise Kiley
Sector focus
Frequently asked questions
What investment stages does Omega Funds target?
Omega Funds invests across the company lifecycle, from early-stage seed and start-up rounds through expansion, late-stage growth, PIPEs, and direct secondary transactions. It also evaluates spin-off and divestiture opportunities. The firm's multi-stage approach allows it to support biotech companies from inception to pre-IPO.
Which sectors does Omega Funds focus on?
The firm invests exclusively in the life sciences sector, targeting therapeutics across multiple disease areas. Its website emphasizes a platform-centric approach—backing companies developing impactful products rather than single-asset plays. No investments outside human health are indicated in available materials.
Who runs Omega Funds?
Omega Funds' website states its people have the experience, commitment and connections to help entrepreneurs increase their odds of success, but it does not publicly list named principals, managing partners, or an organizational chart. Without a detailed team page or third-party citation, the investment leadership remains unidentified in public sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: